Peripheral Vascular Disease (PVD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Managing Peripheral Vascular Disease: A Short Summary of a Long History
A look back at a decade of advances in management of peripheral vascular disease prompted this short summary of big changes. (Source: ConsultantLive)
Source: ConsultantLive - October 10, 2018 Category: Internal Medicine Authors: Gregory W. Rutecki, MD Tags: Cardiovascular Disease Hypertension Source Type: news

AHA: Doctors Could Do More to Help Smokers With Poor Circulation
WEDNESDAY, Oct. 3, 2018 (American Heart Association) -- Doctors are not doing nearly enough to help peripheral artery disease patients quit smoking, a key risk factor for the disease, a new study shows. The study, published Oct. 3 in the Journal of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 3, 2018 Category: General Medicine Source Type: news

Cardiovascular Systems touts first OUS use of orbital atherectomy system, eyes shift to revascularization
Cardiovascular Systems (NSDQ:CSII) today touted that its peripheral orbital atherectomy system was used in its first procedure outside the US as the company is reportedly looking to grow its business beyond a single product and towards supplying a full revascularization tool kit. The St. Paul, Minn.-based company said that its Stealth 360 peripheral orbital atherectomy system was used to treat a patient in Hong Kong, which marks the first commercial use of the company’s product outside the US. “We are pleased that the first patient treated with OAS in conjunction with our international distribution partner, Or...
Source: Mass Device - September 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular Cardiovascular Systems Inc. Source Type: news

Ra Medical sets range for $50m IPO
Ra Medical yesterday set the terms for its forthcoming initial public offering, which would fetch $50 million at the midpoint. The Carlsbad, Calif.-based company said it plans to float 3.3 million shares at $14 to $16 apiece, for gross proceeds of $46.7 million to $53.3 million. At the midpoint the flotation would gross $50.0 million, according to a new filing with the U.S. Securities & Exchange Commission. That’s well below the more than $86 million Ra Medical indicated in a regulatory filing last month. The company makes the Dabra atherectomy catheter laser to treat patients with peripheral artery disease. The...
Source: Mass Device - September 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Funding Roundup Initial Public Offering (IPO) Wall Street Beat peripheral Ra Medical Source Type: news

CWRU receives NIH funding to investigate new imaging approach for peripheral vascular disease
(Case Western Reserve University) Case Western Reserve University School of Medicine has received a three-year, $1,118,556 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to investigate a new imaging approach for diagnosing peripheral arterial disease, a common and potentially serious circulatory problem. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 17, 2018 Category: International Medicine & Public Health Source Type: news

Slow Medicine: Overuse of Genetic Testing, Dialysis
(MedPage Today) -- Plus screening for peripheral artery disease and colon cancer surveillance (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2018 Category: Cardiology Source Type: news

Avinger shareholders accept $5 million settlement
The plaintiffs in a class action suit against Avinger (NSDQ:AVGR) have approved the $5 million settlement that the company offered in March. Shareholders sued the company and several of its officers and directors claiming that they made false and misleading statements about Avinger’s original product, Pantheris, in its 2015 initial public offering. Avinger makes image-guided, catheter-based atherectomy systems for treatment of peripheral artery disease. The company has already paid its $1.75 million portion of the settlement. Avinger sold approximately 5 million shares to members of the public in its IPO at $13.00 p...
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiovascular Catheters Food & Drug Administration (FDA) Initial Public Offering (IPO) Legal News Avinger Source Type: news

Beet juice may reduce walking pain with leg artery disease
(Reuters Health) - Patients with peripheral artery disease who drink beet juice before walking may feel less pain from this type of exercise than people who don't, a small experiment suggests. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Peripheral artery disease in diabetics can be predicted by AI
Artificial intelligence blood test can predict peripheral artery disease in patients with diabetes, according to research presented at the European Society of Cardiology Congress.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 7, 2018 Category: Endocrinology Source Type: news

Avinger asks for FDA approval of small-vessel PAD device
Avinger (NASDAQ:AVGR) has filed for 510(k) clearance of its Pantheris small-vessel “lumivascular” atherectomy device for treatment of peripheral artery disease (PAD). The Pantheris small vessel (SV) device extends the company’s line of Pantheris catheters, the first and only image-guided atherectomy devices for the treatment of PAD, which is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Designed with a lower profile and longer length, Pantheris SV is intended to expand the number of addressable procedures for Pantheris by allowing physicians to target lesions in smaller-di...
Source: Mass Device - August 30, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: 510(k) Blog Regulatory/Compliance Vascular Avinger FDA Source Type: news

Ra Medical re-ups $86m IPO registration
Ra Medical has re-upped its registration for an upcoming initial public offering looking to bring in approximately $86.3 million, according to a recently posted SEC filing. Ra Medical produces the Dabra atherectomy catheter laser designed to treat patients with peripheral artery disease. The system is designed to destroy arteriosclerotic blockages through the use of radiation ablation, which the company touts as having significant advantages over traditional balloon angioplasty systems. Ra Medical won FDA 510(k) clearance for the system last May, and CE Mark approval in the European Union in 2016. The Carlsbad, Calif.-...
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Ra Medical Source Type: news

Scientists develop alternative treatment for peripheral artery disease
(Louisiana State University) Cristina Sabliov, LSU Biological and Agricultural Engineering professor, and Tammy Dugas, professor in the LSU School of Veterinary Medicine's Department of Comparative Biomedical Sciences, have joined forces to fight peripheral artery disease, or PAD, an ailment affecting 8 million Americans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2018 Category: International Medicine & Public Health Source Type: news

EC Approves Rivaroxaban Plus Aspirin Regimen for CAD, PAD EC Approves Rivaroxaban Plus Aspirin Regimen for CAD, PAD
The rivaroxaban/aspirin combination is for the prevention of thrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 27, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

24.08.18: Not intended for U.S. and UK Media
Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery diseaseXarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germanymehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 24, 2018 Category: Pharmaceuticals Source Type: news

Bayer secures approval in the EU for Xarelto ® (rivaroxaban) for patients with coronary or peripheral artery disease (for specialized target groups only)
Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germany (Source: Bayer Company News)
Source: Bayer Company News - August 24, 2018 Category: Pharmaceuticals Source Type: news